Propofol directly induces caspase-1-dependent macrophage pyroptosis through the NLRP3-ASC inflammasome.
Animals
CARD Signaling Adaptor Proteins
/ metabolism
Caspase 1
/ genetics
Cell Survival
/ drug effects
Gene Knockout Techniques
Humans
Inflammasomes
/ metabolism
Macrophages
/ metabolism
Male
Mice
Mice, Inbred C57BL
NLR Family, Pyrin Domain-Containing 3 Protein
/ metabolism
Propofol
/ pharmacology
Pyroptosis
/ drug effects
RAW 264.7 Cells
Signal Transduction
/ drug effects
THP-1 Cells
Transfection
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
17 07 2019
17 07 2019
Historique:
received:
24
02
2019
accepted:
24
06
2019
revised:
21
06
2019
entrez:
19
7
2019
pubmed:
19
7
2019
medline:
4
8
2020
Statut:
epublish
Résumé
Propofol infusion syndrome (PRIS) is an uncommon life-threatening complication observed most often in patients receiving high-dose propofol. High-dose propofol treatment with a prolonged duration can damage the immune system. However, the associated molecular mechanisms remain unclear. An increasing number of clinical and experimental observations have demonstrated that tissue-resident macrophages play a critical role in immune regulation during anaesthesia and procedural sedation. Since the inflammatory response is essential for mediating propofol-induced cell death and proinflammatory reactions, we hypothesised that propofol overdose induces macrophage pyroptosis through inflammasomes. Using primary cultured bone marrow-derived macrophages, murine macrophage cell lines (RAW264.7, RAW-asc and J774) and a mouse model, we investigated the role of NLRP3 inflammasome activation and secondary pyroptosis in propofol-induced cell death. We found that high-dose propofol strongly cleaved caspase-1 but not caspase-11 and biosynthesis of downstream interleukin (IL)-1β and IL-18. Inhibition of caspase-1 activity blocks IL-1β production. Moreover, NLRP3 deletion moderately suppressed cleaved caspase-1 as well as the proportion of pyroptosis, while levels of AIM2 were increased, triggering a compensatory pathway to pyroptosis in NLRP3
Identifiants
pubmed: 31316052
doi: 10.1038/s41419-019-1761-4
pii: 10.1038/s41419-019-1761-4
pmc: PMC6637184
doi:
Substances chimiques
CARD Signaling Adaptor Proteins
0
Inflammasomes
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
NLRP3 protein, human
0
Nlrp3 protein, mouse
0
PYCARD protein, human
0
Pycard protein, mouse
0
Casp1 protein, mouse
EC 3.4.22.36
Caspase 1
EC 3.4.22.36
Propofol
YI7VU623SF
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
542Références
Hepatology. 2014 Mar;59(3):898-910
pubmed: 23813842
Anesthesiology. 2012 Apr;116(4):868-81
pubmed: 22334036
Nat Immunol. 2011 Mar;12(3):222-30
pubmed: 21151103
Neurotox Res. 2016 Oct;30(3):434-52
pubmed: 27189477
Crit Care Med. 2018 Jan;46(1):e91-e94
pubmed: 29252954
J Neuroinflammation. 2018 Apr 17;15(1):109
pubmed: 29665808
Proc Natl Acad Sci U S A. 2016 Jun 14;113(24):E3441-50
pubmed: 27247388
Nature. 2009 Jul 9;460(7252):269-73
pubmed: 19494813
Anesthesiology. 2015 Nov;123(5):1067-83
pubmed: 26352374
Anesth Analg. 1987 Dec;66(12):1256-63
pubmed: 3500657
Br J Anaesth. 2006 Aug;97(2):268
pubmed: 16831883
Br J Anaesth. 2007 Sep;99(3):368-75
pubmed: 17621602
Kidney Int. 2007 Aug;72(3):290-9
pubmed: 17440493
Crit Care. 2015 Nov 12;19:398
pubmed: 26558513
Br J Anaesth. 2014 Feb;112(2):210-2
pubmed: 24431349
Nature. 2009 Mar 26;458(7237):509-13
pubmed: 19158676
Neuropharmacology. 2018 Jan;128:63-75
pubmed: 28963039
Anesthesiology. 2003 May;98(5):1178-85
pubmed: 12717140
Immunity. 2013 Aug 22;39(2):311-323
pubmed: 23954133
Anesthesiology. 2015 Feb;122(2):343-52
pubmed: 25296107
Cell Death Dis. 2017 Feb 2;8(2):e2579
pubmed: 28151471
Toxicol In Vitro. 2012 Sep;26(6):862-71
pubmed: 22579810
Cell Rep. 2018 Nov 27;25(9):2339-2353.e4
pubmed: 30485804
Cell Death Dis. 2015 Jul 09;6:e1813
pubmed: 26158519
Nat Immunol. 2010 Oct;11(10):936-44
pubmed: 20729857
Cell Res. 2015 Dec;25(12):1285-98
pubmed: 26611636
Anesth Analg. 1999 Nov;89(5):1250-6
pubmed: 10553845
Immunity. 2012 Mar 23;36(3):401-14
pubmed: 22342844
Intensive Care Med. 2003 Sep;29(9):1417-25
pubmed: 12904852
PLoS One. 2011 Feb 24;6(2):e17152
pubmed: 21390329
Cell Death Dis. 2013 May 23;4:e644
pubmed: 23703389
Anesth Analg. 1995 Dec;81(6):1269-74
pubmed: 7486115
Environ Toxicol. 2017 Dec;32(12):2440-2454
pubmed: 28804952
Inflammation. 2016 Dec;39(6):2094-2103
pubmed: 27696022
Immunity. 2016 Mar 15;44(3):450-462
pubmed: 26982353
Immunol Rev. 2015 May;265(1):35-52
pubmed: 25879282
Ann N Y Acad Sci. 2005 May;1042:262-71
pubmed: 15965071
J Anesth. 2008;22(3):263-77
pubmed: 18685933
Nature. 2011 Jan 13;469(7329):221-5
pubmed: 21124315